Adult immunisation register ‘high priority’

The PBAC’s first mention of a national register follows its recommendation to include the shingles vaccine Zostavax (bioCSL) on the National Immunisation  Program for 70-year-olds and a catch-up program for patients  aged 71–79 years.

Associate Professor Kristine Macartney, of the National Centre for Immunisation Research & Surveillance (NCIRS), said it’s the first time in a decade that the committee has recommended funding a vaccine for adults – the NIP currently only funds seasonal influenza and pneumococcal vaccines in adults.

Should the PBS accept the latest recommendation,